← Leaderboards
Darren K McGuire
University Of Texas Sw Med Ctr/Dallas
$133,127
Attributed
$133,127
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $108K · FY2005–07$200K$150K$100K$50K$0
'05
'06
'07
Funding mix
By agency
NIH$133,127 · 3
By mechanism
M01$133,127 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- Craig R. Malloy$13,817,010
- Christopher B Newgard$30,587,994
- Richard J. Barohn$34,290,842
- Peter John Espenshade$14,189,166
- Charles Y.c Pak$11,557,463
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCardiacCardiovascular DiseasesCardiovascular Risk FactorCardiovascular SystemClinical ResearchCollaborationsComputer Retrieval Of Information On Scientific Projects DatabaseDepositionDiabetes Mellitus, Non-Insulin-DependentDouble-Blind MethodExerciseFundingGrantHeartHospitalsHyperglycemiaInstitutionLipidsMagnetic Resonance ImagingMyocardialMyocytes, CardiacNuclear Magnetic ResonanceOutpatients
Grant awards (3)
ROSIGLITAZONE VS PLACEBO: EFFECT OF CV PERFORMANCE AND MYOCARDIAL TRIGLYCERIDE$13,052
M01 · FY2007 · RR · contact PI
ROSIGLITAZONE VS PLACEBO: EFFECT OF CV PERFORMANCE AND MYOCARDIAL TRIGLYCERIDE$108,043
M01 · FY2006 · RR · contact PI
ROSIGLITAZONE VS PLACEBO: EFFECT OF CV PERFORMANCE AND MYOCARDIAL TRIGLYCERIDE$12,032
M01 · FY2005 · RR